Published in PLoS Pathog on May 15, 2009
Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell (2009) 5.06
Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe (2009) 3.58
Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 3.47
Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J Virol (2009) 3.13
Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med (2011) 2.98
HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harb Perspect Med (2012) 2.72
Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev (2010) 2.55
Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host Microbe (2010) 2.44
The cell biology of HIV-1 virion genesis. Cell Host Microbe (2009) 2.41
The restriction factors of human immunodeficiency virus. J Biol Chem (2012) 2.36
Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses. J Virol (2013) 2.28
Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci U S A (2009) 2.21
Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog (2010) 2.12
Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV. Cell Host Microbe (2011) 2.11
Innate sensing of HIV-1 assembly by Tetherin induces NFκB-dependent proinflammatory responses. Cell Host Microbe (2012) 2.03
The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog (2010) 1.94
Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog (2010) 1.89
HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology (2010) 1.87
Human cellular restriction factors that target HIV-1 replication. BMC Med (2009) 1.86
IFITM proteins restrict viral membrane hemifusion. PLoS Pathog (2013) 1.86
Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol (2010) 1.83
BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol (2010) 1.82
Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog (2010) 1.73
Animal models for HIV/AIDS research. Nat Rev Microbiol (2012) 1.71
Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc Natl Acad Sci U S A (2010) 1.71
Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol (2010) 1.69
Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J Virol (2010) 1.67
CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. J Virol (2010) 1.63
Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses. J Virol (2010) 1.61
Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol (2010) 1.60
Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog (2012) 1.60
Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci U S A (2011) 1.56
The evolution of HIV-1 and the origin of AIDS. Philos Trans R Soc Lond B Biol Sci (2010) 1.54
The great escape: viral strategies to counter BST-2/tetherin. PLoS Pathog (2010) 1.52
Novel approaches to inhibiting HIV-1 replication. Antiviral Res (2009) 1.48
Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol (2010) 1.47
Intrinsic cellular defenses against human immunodeficiency viruses. Immunity (2012) 1.45
Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology (2010) 1.40
Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J Virol (2010) 1.40
Interplay between ovine bone marrow stromal cell antigen 2/tetherin and endogenous retroviruses. J Virol (2010) 1.39
Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc Natl Acad Sci U S A (2010) 1.39
Antiviral activity of the interferon-induced cellular protein BST-2/tetherin. AIDS Res Hum Retroviruses (2009) 1.35
The mouse "xenotropic" gammaretroviruses and their XPR1 receptor. Retrovirology (2010) 1.35
Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations. Proc Natl Acad Sci U S A (2010) 1.29
Quantitative multicolor super-resolution microscopy reveals tetherin HIV-1 interaction. PLoS Pathog (2011) 1.29
Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc Natl Acad Sci U S A (2014) 1.26
Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology (2010) 1.26
Mechanism of HIV-1 virion entrapment by tetherin. PLoS Pathog (2013) 1.24
Host and viral determinants of Mx2 antiretroviral activity. J Virol (2014) 1.23
HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2. Retrovirology (2014) 1.22
A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. PLoS Pathog (2012) 1.21
Vpu binds directly to tetherin and displaces it from nascent virions. PLoS Pathog (2013) 1.21
SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and facilitate virion release. PLoS Pathog (2011) 1.20
BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action. Virology (2011) 1.20
HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef. Retrovirology (2011) 1.18
Endogenous CD317/Tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses. J Virol (2010) 1.17
Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens. J Virol (2011) 1.14
Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. PLoS Pathog (2014) 1.14
Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology (2011) 1.14
Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice. J Virol (2012) 1.14
Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction. Viruses (2011) 1.13
Structural and biophysical analysis of BST-2/tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release. J Biol Chem (2010) 1.13
The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J Infect Dis (2011) 1.10
Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones. Cold Spring Harb Perspect Med (2012) 1.09
HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. Mol Aspects Med (2010) 1.09
Counteraction of the multifunctional restriction factor tetherin. Front Microbiol (2014) 1.09
Influenza virus is not restricted by tetherin whereas influenza VLP production is restricted by tetherin. Virology (2011) 1.08
Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein. PLoS Pathog (2012) 1.08
β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release. Retrovirology (2011) 1.07
The inability to disrupt the immunological synapse between infected human T cells and APCs distinguishes HIV-1 from most other primate lentiviruses. J Clin Invest (2009) 1.07
Misdirection of membrane trafficking by HIV-1 Vpu and Nef: Keys to viral virulence and persistence. Cell Logist (2011) 1.06
Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. J Virol (2011) 1.05
Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis. PLoS Pathog (2013) 1.05
Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology (2012) 1.05
Simian immunodeficiency virus SIVagm from African green monkeys does not antagonize endogenous levels of African green monkey tetherin/BST-2. J Virol (2009) 1.05
Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1. J Virol (2011) 1.05
Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection. J Virol (2011) 1.04
Tetherin inhibits prototypic foamy virus release. Virol J (2011) 1.02
Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts. J Virol (2012) 1.02
Tetherin does not significantly restrict dendritic cell-mediated HIV-1 transmission and its expression is upregulated by newly synthesized HIV-1 Nef. Retrovirology (2011) 1.01
BST-2 diminishes HIV-1 infectivity. J Virol (2010) 1.00
Nef proteins of epidemic HIV-1 group O strains antagonize human tetherin. Cell Host Microbe (2014) 0.99
HIV-1 Nef and Vpu are functionally redundant broad-spectrum modulators of cell surface receptors, including tetraspanins. J Virol (2014) 0.99
The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor? J Interferon Cytokine Res (2010) 0.98
Differential regulation of NF-κB-mediated proviral and antiviral host gene expression by primate lentiviral Nef and Vpu proteins. Cell Rep (2015) 0.98
Regulation of porcine endogenous retrovirus release by porcine and human tetherins. J Virol (2009) 0.98
Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. PLoS Pathog (2011) 0.98
HIV-1-induced AIDS in monkeys. Science (2014) 0.97
Modulation of Immune System by Kaposi's Sarcoma-Associated Herpesvirus: Lessons from Viral Evasion Strategies. Front Microbiol (2012) 0.97
TRIM5α and Species Tropism of HIV/SIV. Front Microbiol (2012) 0.96
Immune evasion by Kaposi's sarcoma-associated herpesvirus. Future Microbiol (2010) 0.96
Host gene evolution traces the evolutionary history of ancient primate lentiviruses. Philos Trans R Soc Lond B Biol Sci (2013) 0.95
Efficient SIVcpz replication in human lymphoid tissue requires viral matrix protein adaptation. J Clin Invest (2012) 0.95
Tetherin restricts herpes simplex virus 1 and is antagonized by glycoprotein M. J Virol (2013) 0.95
Host genes important to HIV replication and evolution. Cold Spring Harb Perspect Med (2012) 0.95
Antiretroviral restriction factors. Curr Opin Virol (2011) 0.93
BST-2 mediated restriction of simian-human immunodeficiency virus. Virology (2010) 0.93
HIV-1 Nef responsiveness is determined by Env variable regions involved in trimer association and correlates with neutralization sensitivity. Cell Rep (2013) 0.92
Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. Cell Host Microbe (2012) 0.92
Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene (1989) 60.30
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Initial sequence of the chimpanzee genome and comparison with the human genome. Nature (2005) 25.67
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature (2004) 17.56
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature (2008) 14.99
Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell (1991) 13.69
Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature (1999) 10.97
The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe (2008) 9.27
A molecular clone of HTLV-III with biological activity. Nature (1985) 8.30
AIDS as a zoonosis: scientific and public health implications. Science (2000) 8.28
Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science (1990) 8.07
Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses (1987) 7.85
Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci U S A (2005) 6.85
Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol (2000) 6.47
A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science (1988) 6.30
The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol (1990) 6.08
The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res Hum Retroviruses (1990) 5.79
Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A (1989) 5.72
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J (2004) 5.67
Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci U S A (2001) 5.46
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol (2004) 5.35
Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic (2003) 5.32
A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol (2005) 5.24
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A (2004) 5.15
An African primate lentivirus (SIVsm) closely related to HIV-2. Nature (1989) 5.03
Influenza viruses select ordered lipid domains during budding from the plasma membrane. J Biol Chem (1999) 4.83
Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol (2004) 4.76
Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol (2008) 4.72
Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol (2005) 4.64
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol (1995) 4.45
Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A (2009) 4.38
HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe (2009) 4.36
Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature (1986) 4.35
Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog (2009) 4.18
An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe (2007) 4.17
Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol (1994) 4.14
Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell (2006) 4.13
Inhibition of Lassa and Marburg virus production by tetherin. J Virol (2008) 3.98
HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog (2006) 3.97
Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol (1989) 3.90
Hybrid origin of SIV in chimpanzees. Science (2003) 3.75
A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci U S A (2004) 3.73
Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol (1999) 3.66
A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci U S A (2004) 3.60
Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog (2006) 3.57
The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol (1996) 3.56
Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection. J Exp Med (1993) 3.29
Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci U S A (2003) 3.05
Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J Virol (2005) 3.03
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A (2004) 2.99
Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol (1998) 2.94
Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci (2007) 2.90
Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology (2004) 2.80
Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics (1995) 2.65
The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci U S A (2000) 2.42
A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation. J Virol (1997) 2.41
In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A (2003) 2.32
Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways. Microbiol Mol Biol Rev (2006) 2.25
The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor? J Virol (1996) 2.21
The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology (1995) 2.08
Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates. Virology (1995) 2.08
Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol (2005) 1.97
Generation of simian-tropic HIV-1 by restriction factor evasion. Science (2006) 1.84
Lipid composition and fluidity of the human immunodeficiency virus. Proc Natl Acad Sci U S A (1988) 1.79
A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A (2009) 1.76
Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc Natl Acad Sci U S A (2003) 1.69
Simian and human immunodeficiency virus Nef proteins use different surfaces to downregulate class I major histocompatibility complex antigen expression. J Virol (2000) 1.66
Nef increases infectivity of HIV via lipid rafts. Curr Biol (2001) 1.64
Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc Natl Acad Sci U S A (2006) 1.63
Identification of a new simian immunodeficiency virus lineage with a vpu gene present among different cercopithecus monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. J Virol (2003) 1.61
Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. Proc Natl Acad Sci U S A (2007) 1.56
HIV-1 Vpu inhibits accumulation of the envelope glycoprotein within clathrin-coated, Gag-containing endosomes. Cell Microbiol (2007) 1.53
Function of human immunodeficiency virus type 1 Vpu protein in various cell types. J Gen Virol (1995) 1.52
DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol (2005) 1.52
Induction of AIDS in rhesus monkeys by a recombinant simian immunodeficiency virus expressing nef of human immunodeficiency virus type 1. J Virol (1999) 1.47
Cell type-dependence for Vpu function. J Med Primatol (1994) 1.47
Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain. J Virol (1996) 1.46
Structural and functional analysis of the membrane-spanning domain of the human immunodeficiency virus type 1 Vpu protein. Virology (1998) 1.33
Origins of simian immunodeficiency virus infection in macaques at the New England Regional Primate Research Center. J Med Primatol (1995) 1.32
Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology (2003) 1.32
Human immunodeficiency virus type 1 derivative with 7% simian immunodeficiency virus genetic content is able to establish infections in pig-tailed macaques. J Virol (2007) 1.27
HIV/AIDS: virus kept on a leash. Nature (2008) 1.13
Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239. PLoS Pathog (2009) 1.12
The nef gene products of both simian and human immunodeficiency viruses enhance virus infectivity and are functionally interchangeable. J Virol (1997) 1.03
Intracellular restriction factors in mammalian cells--An ancient defense system finds a modern foe. Curr HIV Res (2006) 0.95
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Adjuvant docetaxel for node-positive breast cancer. N Engl J Med (2005) 8.00
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog (2009) 4.18
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol (2013) 3.67
TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol (2010) 3.21
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
The restriction factors of human immunodeficiency virus. J Biol Chem (2012) 2.36
Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane Database Syst Rev (2010) 2.35
Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33
Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha. Proc Natl Acad Sci U S A (2006) 2.16
Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV. Cell Host Microbe (2011) 2.11
The dog as a cancer model. Nat Biotechnol (2006) 2.08
An approach to high resolution diffusion tensor imaging in fixed primate brain. Neuroimage (2007) 2.04
CD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood. Am J Pathol (2006) 1.92
BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol (2010) 1.82
Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS. J Clin Invest (2005) 1.78
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis (2011) 1.76
Analysis of copy number variation in the rhesus macaque genome identifies candidate loci for evolutionary and human disease studies. Hum Mol Genet (2008) 1.73
Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene (2003) 1.73
Animal models for HIV/AIDS research. Nat Rev Microbiol (2012) 1.71
ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog (2012) 1.60
Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol (2009) 1.55
Diversity of stx2 converting bacteriophages induced from Shiga-toxin-producing Escherichia coli strains isolated from cattle. Microbiology (2004) 1.53
Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther (2005) 1.50
Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer (2004) 1.46
Serial diffusion tensor MRI after transient and permanent cerebral ischemia in nonhuman primates. Stroke (2006) 1.42
Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. Clin Cancer Res (2004) 1.33
Experimental rhesus lymphocryptovirus infection in immunosuppressed macaques: an animal model for Epstein-Barr virus pathogenesis in the immunosuppressed host. Blood (2004) 1.32
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res (2012) 1.27
Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1. J Immunol (2009) 1.27
Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc Natl Acad Sci U S A (2014) 1.26
Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res (2007) 1.26
The TRIM5{alpha} genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting-dose intrarectal challenge. J Virol (2011) 1.26
SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine (2011) 1.23
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest (2014) 1.18
In vivo proton magnetic resonance spectroscopy reveals region specific metabolic responses to SIV infection in the macaque brain. BMC Neurosci (2009) 1.16
KIR polymorphisms modulate peptide-dependent binding to an MHC class I ligand with a Bw6 motif. PLoS Pathog (2011) 1.14
Rapid dissemination of SIV following oral inoculation. AIDS (2004) 1.12
Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clin Cancer Res (2004) 1.12
Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239. PLoS Pathog (2009) 1.12
STAT3 upregulates the protein expression and transcriptional activity of β-catenin in breast cancer. Int J Clin Exp Pathol (2010) 1.07
Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. Breast (2007) 1.06
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol (2005) 1.06
Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis. PLoS Pathog (2013) 1.05
Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J Virol (2011) 1.05
Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine (2011) 1.01
Predictors of distress and quality of life in patients undergoing cancer therapy: impact of treatment type and decisional role. Psychooncology (2010) 1.01
Phage-mediated Shiga toxin 2 gene transfer in food and water. Appl Environ Microbiol (2009) 1.00
A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV. J Virol (2011) 0.99
Counteraction of HLA-C-mediated immune control of HIV-1 by Nef. J Virol (2010) 0.99
Novel marmoset (Callithrix jacchus) model of human Herpesvirus 6A and 6B infections: immunologic, virologic and radiologic characterization. PLoS Pathog (2013) 0.99
Refinement of primate copy number variation hotspots identifies candidate genomic regions evolving under positive selection. Genome Biol (2011) 0.99
A brief history of TRIM5alpha. AIDS Rev (2007) 0.98
The formation of inflammatory demyelinated lesions in cerebral white matter. Ann Neurol (2014) 0.98
In vivo replication of T4 and T7 bacteriophages in germ-free mice colonized with Escherichia coli. Virology (2009) 0.98
APOBEC3G polymorphism as a selective barrier to cross-species transmission and emergence of pathogenic SIV and AIDS in a primate host. PLoS Pathog (2013) 0.98
Host genes important to HIV replication and evolution. Cold Spring Harb Perspect Med (2012) 0.95
Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). Curr Cancer Drug Targets (2011) 0.94
Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo. J Virol (2008) 0.94
Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions. J Virol (2011) 0.94
RB regulates pancreas development by stabilizing Pdx1. EMBO J (2011) 0.93
Clinical and biological significance of GSK-3β inactivation in breast cancer-an immunohistochemical study. Hum Pathol (2010) 0.93
Simian immunodeficiency virus envelope compartmentalizes in brain regions independent of neuropathology. J Neurovirol (2006) 0.92
Selective downmodulation of HLA-A and -B by Nef alleles from different groups of primate lentiviruses. Virology (2007) 0.92
Gain-of-sensitivity mutations in a Trim5-resistant primary isolate of pathogenic SIV identify two independent conserved determinants of Trim5α specificity. PLoS Pathog (2013) 0.91
Diversity of envelope genes from an uncloned stock of SIVmac251. AIDS Res Hum Retroviruses (2010) 0.91
KIR3DL01 recognition of Bw4 ligands in the rhesus macaque: maintenance of Bw4 specificity since the divergence of apes and Old World monkeys. J Immunol (2014) 0.90
Sequence variations in HIV-1 p24 Gag-derived epitopes can alter binding of KIR2DL2 to HLA-C*03:04 and modulate primary natural killer cell function. AIDS (2014) 0.89
Pushing the endogenous envelope. Philos Trans R Soc Lond B Biol Sci (2013) 0.88
Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. Am J Clin Oncol (2007) 0.87
Complement synthesis and activation in the brain of SIV-infected monkeys. J Neuroimmunol (2004) 0.87
Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques. PLoS One (2011) 0.86
Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology (2014) 0.85
New insights into the neuroimmunity of SIV infection by magnetic resonance spectroscopy. J Neuroimmune Pharmacol (2006) 0.84
Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. Clin Breast Cancer (2002) 0.84
Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge. J Virol (2010) 0.84
Clinically validated benchmarking of normalisation techniques for two-colour oligonucleotide spotted microarray slides. Appl Bioinformatics (2003) 0.83
Tetherin upregulation in simian immunodeficiency virus-infected macaques. J Virol (2013) 0.82
Susceptibility to repeated, low-dose, rectal SHIVSF162P3 challenge is independent of TRIM5 genotype in rhesus macaques. AIDS Res Hum Retroviruses (2013) 0.81
Plakoglobin interacts with the transcription factor p53 and regulates the expression of 14-3-3σ. J Cell Sci (2013) 0.81
CD8-predominant T-cell CNS infiltration accompanies GVHD in primates and is improved with immunoprophylaxis. Blood (2014) 0.81
Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIVSF162P3N molecular clones in rhesus macaques. Retrovirology (2013) 0.80
A novel recombinant retrovirus in the genomes of modern birds combines features of avian and mammalian retroviruses. J Virol (2013) 0.80
A machine learned classifier that uses gene expression data to accurately predict estrogen receptor status. PLoS One (2013) 0.79
Effect of B-cell depletion on coreceptor switching in R5 simian-human immunodeficiency virus infection of rhesus macaques. J Virol (2011) 0.79
Learning to predict relapse in invasive ductal carcinomas based on the subcellular localization of junctional proteins. Breast Cancer Res Treat (2009) 0.79